Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RVMDBullishIndustry Newsnews

High materiality7/10

RVMD launches Phase 3 RASolve 308 in G12D NSCLC, data boost optimism

Oct 20, 2026, 1:17 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Phase 3 initiation plus supportive monotherapy data provides a plausible near-term re-rating; past biotech moves show sensitivity to trial milestones and data refreshes.

AI summary

What happened, with direct paths to the underlying reporting

Revolution Medicines has started treating patients in global Phase 3 RASolve 308, evaluating zoldonrasib with pembrolizumab and platinum-based chemo for first-line G12D NSCLC. April 2025 monotherapy data showed ORR 61% and DCR 89% at 1200 mg QD, supporting activity. The Phase 3 readout could be a near-term stock driver if results align with early signals.

RVMD begins global Phase 3 RASolve 308 for zoldonrasib in G12D NSCLC.
Trial compares zoldonrasib with pembrolizumab and platinum doublet vs placebo.
April 2025 monotherapy data shows high activity in KRAS G12D NSCLC.
RVMD stock rose about 6.9% intraday on news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.